Acutaas Chemicals Ltd
ACUTAASAcutaas Chemicals Ltd is strength at full price. The numbers are improving — and a P/E at the 80th percentile of its own range says the market knows.
The sharpest disagreement: the engine is strong, but at the 80th percentile of its own range you are paying full price for it.
The price is in a confirmed uptrend (124 weeks in) while the P/E sits at the 80th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +70.5% year on year, and 95% of the last 3 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Acutaas Chemicals Ltd trades at ₹3,384, in a confirmed uptrend and 124 weeks into that stage. That is +26.3% against its own 200-day average. It sits at 87% of a 52-week range of ₹1,300 to ₹3,695. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 55 straight weeks.
Today the stock is in a confirmed uptrend — week 124 of stage 2, confirmed. At ₹3,384 it trades +26.3% versus its 200-day average and sits at 87% of its 52-week range (₹1,300–₹3,695).
Against the market, two honest reads. Cumulative: over the last 5.0 years the stock moved +457% while the NIFTY 500 moved +53% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 55 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Acutaas Chemicals Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: mid_expansion_with_peak_margin_value_trap. Our fortnightly research layers last read it on 22 August 2026.
Our read, 22 August 2026. Acutaas has customer-linked CDMO, battery and semiconductor growth engines, but the valuation assumes that elevated profitability survives lower-margin mix and repeated project-timing changes.
What is proven. Acutaas has customer-linked CDMO, battery and semiconductor growth engines, but the valuation assumes that elevated profitability survives lower-margin mix and repeated project-timing changes.
What is not proven yet. The thesis breaks if CDMO approvals and commercial ramp fail to offset lower-margin battery mix, causing blended operating margin to remain below the stated full-year range for two consecutive reported quarters.
🚨 What would change our mind. The thesis breaks if CDMO approvals and commercial ramp fail to offset lower-margin battery mix, causing blended operating margin to remain below the stated full-year range for two consecutive reported quarters.
Layer 2 read, 22 August 2026 — BENCH. Real CDMO progress is being asked to outrun a supply wave and another moved project date. Acutaas' June-quarter revenue and profit still rose year on year, and the sector review confirms its gross-margin gain came from product mix. But that same review names Acutaas among seven companies that moved a dated commitment, matching the Product 3 completion change. With sector supply expanding, the external test supports waiting.
What would change Layer 2’s mind. Flip BENCH to ADVANCE if Product 3 commissions by end-Q2 FY27 and the next sector capital-flow block no longer reads SUPPLY_FLOOD; flip to DROP if another Acutaas project date moves while commercial revenue remains undisclosed.
The test written in advance. The thesis breaks if CDMO approvals and commercial ramp fail to offset lower-margin battery mix, causing blended operating margin to remain below the stated full-year range for two consecutive reported quarters. — the thesis as written as stated by the next result.
What the company does. Recent earnings growth is operating-led and the newest quarter confirms commercial battery supply. The next proof points are CDMO product ramp, Product 3 commissioning and Indichem execution. The trailing multiple understates risk if margins return toward the company’s mid-cycle level.
Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Acutaas Chemicals Ltd reported ₹330 Cr of revenue in the Jun 26 quarter, +59.4% year on year. That is the 11th straight quarter of year-on-year growth. Over 9 years it has compounded at 26.6% a year. The last full year, FY26, came in at ₹1,339 Cr. The last four reported quarters add to ₹1,462 Cr.
FY26 revenue came in at ₹1,339 Cr (+33.0% on the year), capping 9 years at 26.6% compound. The latest quarter (Jun 26) printed ₹330 Cr, +59.4% year on year — the 11th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +41.7% growth against the decade's 26.6% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +41.0% over the last 4 quarters against +40.6%/yr over the last 8 — stabilising; TTM profit +103.7% vs +203.6%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Acutaas Chemicals Ltd's operating margin is 34.0% in the Jun 26 quarter, +9.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 10 fiscal years the operating margin has ranged 14.0% to 36.0%. The current quarter sits inside that band.
Why this happened. The latest call attributes gross-margin expansion to higher pharma intermediate contribution and reports advanced pharma revenue growth. This applies only if volume and mix continue while lower-margin battery capacity ramps.
The latest quarter's operating margin is 34.0%, +9.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 14.0%–36.0%, and FY26's 36.0% is the top of that band — a record year.
Why the margin moved: operating margin went +9.7 pp year on year while gross margin went +4.7 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Acutaas Chemicals Ltd earned ₹75.0 Cr of net profit in the Jun 26 quarter, +70.5% year on year. It is the 7th consecutive quarter of growth. Full-year FY26 profit was ₹356 Cr. The 9-year compound rate is 45.7%. That is 22.7% of the quarter's revenue. The same quarter a year earlier earned ₹44.0 Cr.
Jun 26 profit was ₹75.0 Cr, +70.5% year on year — the 7th consecutive quarter of growth. On the full year, FY26 printed ₹356 Cr (+122.5%), and the 9-year compound rate is 45.7%.
Why profit moved: revenue contributed +59.4% and the margin +9.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +102.1% vs revenue +41.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 95% of Acutaas Chemicals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹292 Cr of operating cash against ₹356 Cr of profit. After ₹413 Cr of capital spending, ₹−121 Cr was left as free cash.
FY26: operating cash of ₹292 Cr against reported profit of ₹356 Cr, leaving free cash of ₹−121 Cr after ₹413 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 95% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 95%: the cash cycle stretched 69 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 11.0× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Acutaas Chemicals Ltd's cash conversion cycle runs 149 days in FY26, up from 80 days in FY21. Capital spending ran ₹867 Cr over the last 3 years. At FY26 sales of ₹1,339 Cr each day of that cycle holds about ₹3.7 Cr, so roughly ₹547 Cr sits inside the business at any moment.
Why this happened. Management says the battery plant has begun commercial supply and that installed VC and FEC capacity is contracted across several customers. The ramp needs reported revenue disclosure because management did not provide a near-term contribution figure.
FY26: debtors at 99 days, inventory at 149 days — roughly 4.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 149 days, looser than FY21's 80.
The full loop: cash goes out to suppliers and production on day 0; stock waits 149 days to sell; customers pay about 99 days after that; and suppliers themselves are paid at 99 days — netting out to the 149-day cycle.
In money terms: at FY26 sales of ₹1,339 Cr, each day of the cycle holds about ₹3.7 Cr — so the 149-day loop keeps roughly ₹547 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹867 Cr over the last 3 fiscal years against ₹79.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹332 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Acutaas Chemicals Ltd earns a ROCE of 32% in FY26. That is up from a trough of 16% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 26.6% net margin on 0.67× asset turns.
FY26 ROCE is 32%, recovered from a FY24 trough of 16% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 26.6% net margin × 0.67× asset turns × 1.20× balance-sheet leverage ≈ 21.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 22% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Acutaas Chemicals Ltd carries ₹36.0 Cr of borrowings against ₹1,654 Cr of equity in FY26, a debt-to-equity of 0.02. Operating profit covers the interest bill north of 100×. Over 5 years borrowings went from ₹137 Cr to ₹36.0 Cr. Capital spending ran ₹867 Cr across the last 3 of those years.
FY26: borrowings of ₹36.0 Cr against equity of ₹1,654 Cr — a debt-to-equity of 0.02. Operating profit covers the interest bill north of 100×. Over 5 years borrowings went from ₹137 Cr to ₹36.0 Cr while capital spending ran ₹867 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 22% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 8.7 points of Acutaas Chemicals Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 21.6% of the company. Domestic institutions moved +4.7 points over the same window, to 19.6%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +8.7 points over 8 quarters to 21.6%; Domestic institutions: +4.7 points over 8 quarters to 19.6%; Promoters: −3.3 points over 8 quarters to 32.7%.
Why the register moved: foreign institutions drove it (+8.7 points), alongside domestic institutions (+4.7 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Acutaas Chemicals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Acutaas Chemicals Ltd trades at 71.7× P/E, at the pricey end of its own range (80th percentile). Its long-run median P/E is 59.5×, measured across 5.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 71.7× is at the pricey end of its own range (80th percentile), against a long-run median of 59.5× measured over 5.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +124.5% against a +134.6% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +41.0%/yr price move, ~+40.6%/yr came from earnings growth and ~+0.4 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 22% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 25 August 2026 price, Acutaas Chemicals Ltd was paying for profit growth of about 30.9% a year. Profit itself has compounded 45.7% a year over the past 9 years. Today the market pays 71.7× P/E, the 80th percentile of its own 5-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is below what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 25 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Acutaas Chemicals Ltd reads as mixed on its fundamental arc. Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +228.6% at its peak to +103.7% but is still expanding, ROCE lifting at 32.0%. The read is built from 8 quarters across 4 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +33.0% | +29.5% | +31.5% | — |
| Profit | +122.5% | +62.5% | +45.8% | — |
| EPS | +124.5% | +56.1% | +38.4% | — |
| Share price | +134.6% | +72.1% | +41.0% | — |
4-Factor Sector Score
77.3/100 — rank 2 of 24 in Pharma - API & CRAMS · 76% evidence confidence
Acutaas Chemicals Ltd scores 77.3 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 2. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 31.9 + 20.1 + 9.3 + 16 = 77.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Acutaas Chemicals Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
🚨 Electrolyte Additive Phase 2 Timeline Slipped · 24 July 2026. Management moved the completion target for the electrolyte additive Phase 2 capex from Q1 FY '27 in Apr 2026 to the end of Q2 FY27 in Jul 2026, a one-quarter delay to a major capacity milestone. The latest call calls the project on schedule but does not explain the revised date, which could affect the timing of the third product ramp-up.
CDMO Product Ramp-Up Timing Accelerated · 24 July 2026. The latest call now places the four validated CDMO products at peak revenue from H2 FY27, whereas Jan 2026 had confirmed that their ramp-up would be majorly in F'28. This is an unexplained acceleration of the revenue ramp and could materially change the timing embedded in the CDMO outlook.
Lower Stated R&D Molecule Throughput · 24 July 2026. The latest call states an annual molecule-development run rate of 30 to 40 molecules, versus the around 50-odd molecules stated in Jan 2026. Because management has presented the pipeline as a key support for CDMO growth and concentration de-risking, the lower stated throughput is material and was not reconciled or explained.
FY27 Capital Allocation Reversal - Maintenance-Only Commitment Abandoned for Major Undefined Program · 30 April 2026. Management stated in the Oct 2025 call that all growth capex requirements through FY28 were already satisfied and FY27 would consist of maintenance-only spend, a definitive commitment used to anchor investor capital allocation models. The Apr 2026 call contradicts this without explanation by announcing an ambitious R&D center expansion with a planned 10x capacity increase, active land acquisition for new infrastructure, and a 50 crore capex spillover - with the R&D and land costs yet to be finalized - representing a material and unexplained shift in the FY27 capital deployment plan.
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Neuland Laboratories LtdNEULANDLAB | 81.2/100Sector-leading setup100% evidence | LEADER | 33.6/35 Revenue 78.3% · PAT 100% · OPM change 23 pp 100% evidence | 19.9/25 ROCE 26.5% · OPM 35% 100% evidence | 12.0/20 P/E 60.7× · PEG 1.05 100% evidence | 15.7/20 RS sector 7.5% · RS bench 44.6% · 1Y 62.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 33.6 + 19.9 + 12 + 15.7 = 81.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Acutaas Chemicals Ltdthis pageACUTAAS | 77.3/100Favorable setup76% evidence | 31.9/35 Revenue 41% · PAT 100% · OPM change 9 pp 95% evidence | 20.1/25 ROCE 31.6% · OPM 34% 76% evidence | 9.3/20 P/E 71.7× · PEG — 50% evidence | 16.0/20 RS sector 86.5% · RS bench 43.7% · 1Y 129.5%5 of 8 weeks ahead 70% evidence | |
| Exact sum: 31.9 + 20.1 + 9.3 + 16 = 77.3 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3IOL Chemicals & Pharmaceuticals LtdIOLCP | 73.0/100Favorable setup100% evidence | LEADER | 28.5/35 Revenue 18.5% · PAT 60% · OPM change 3 pp 100% evidence | 12.5/25 ROCE 11.3% · OPM 14% 100% evidence | 13.8/20 P/E 32.3× · PEG 0.66 100% evidence | 18.2/20 RS sector 37.2% · RS bench 81.2% · 1Y 100.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.5 + 12.5 + 13.8 + 18.2 = 73 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Laurus Labs LtdLAURUSLABS | 71.2/100Favorable setup93% evidence | LEADER | 32.2/35 Revenue 22.6% · PAT 100% · OPM change 8 pp 100% evidence | 18.2/25 ROCE 17.8% · OPM 32% 100% evidence | 5.3/20 P/E 97.3× · PEG 3.33 65% evidence | 15.5/20 RS sector 22.2% · RS bench 63.4% · 1Y 123.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.2 + 18.2 + 5.3 + 15.5 = 71.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Gland Pharma LtdGLAND | 69.7/100Favorable setup100% evidence | LEADER | 26.4/35 Revenue 17.6% · PAT 46.4% · OPM change 3 pp 100% evidence | 13.9/25 ROCE 15.1% · OPM 27% 100% evidence | 14.2/20 P/E 42.1× · PEG 1.45 100% evidence | 15.2/20 RS sector 8.2% · RS bench 45.5% · 1Y 54.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.9 + 14.2 + 15.2 = 69.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Divis Laboratories LtdDIVISLAB | 65.4/100Favorable setup100% evidence | LEADER | 26.5/35 Revenue 16.4% · PAT 26.8% · OPM change 11 pp 100% evidence | 19.1/25 ROCE 22% · OPM 41% 100% evidence | 3.5/20 P/E 83.1× · PEG 3.45 100% evidence | 16.3/20 RS sector 3.2% · RS bench 39.9% · 1Y 55.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 19.1 + 3.5 + 16.3 = 65.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 7Shilpa Medicare LtdSHILPAMED | 63.1/100Mixed-positive evidence100% evidence | LEADER | 27.6/35 Revenue 28% · PAT 100% · OPM change 1 pp 100% evidence | 10.3/25 ROCE 10.9% · OPM 29% 100% evidence | 5.6/20 P/E 66.1× · PEG 6.86 100% evidence | 19.6/20 RS sector 60.8% · RS bench 111.5% · 1Y 127.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.6 + 10.3 + 5.6 + 19.6 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Sai Life Sciences LtdSAILIFE | 62.9/100Mixed-positive evidence93% evidence | LEADER | 27.2/35 Revenue 17.6% · PAT 48% · OPM change 3 pp 100% evidence | 16.6/25 ROCE 19.6% · OPM 27% 100% evidence | 4.9/20 P/E 91.6× · PEG 3.46 65% evidence | 14.2/20 RS sector 12.7% · RS bench 51.7% · 1Y 84.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 16.6 + 4.9 + 14.2 = 62.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 9Granules India LtdGRANULES | 62.4/100Mixed-positive evidence100% evidence | LEADER | 26.4/35 Revenue 24.8% · PAT 38.1% · OPM change 3 pp 100% evidence | 15.8/25 ROCE 15.5% · OPM 23% 100% evidence | 10.4/20 P/E 34.7× · PEG 1.27 100% evidence | 9.8/20 RS sector 1.7% · RS bench 37.1% · 1Y 77.8%11 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 15.8 + 10.4 + 9.8 = 62.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Windlas Biotech LtdWINDLAS | 53.5/100Mixed-positive evidence77% evidence | BREAKING OUT | 16.7/35 Revenue 18.8% · PAT 9.8% · OPM change -2 pp 83% evidence | 14.5/25 ROCE 15.9% · OPM 11% 95% evidence | 11.5/20 P/E 35.1× · PEG — 50% evidence | 10.8/20 RS sector -1.8% · RS bench 34.7% · 1Y 13.7%5 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 14.5 + 11.5 + 10.8 = 53.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Anthem Biosciences LtdANTHEM | 53.0/100Mixed-positive evidence77% evidence | BREAKING OUT | 12.7/35 Revenue -2.1% · PAT 14.1% · OPM change 1 pp 100% evidence | 22.0/25 ROCE 30.4% · OPM 36% 100% evidence | 9.2/20 P/E 89.3× · PEG — 15% evidence | 9.1/20 RS sector -4.6% · RS bench 29.4% · 1Y 13.4%7 of 12 weeks ahead 70% evidence |
| Exact sum: 12.7 + 22 + 9.2 + 9.1 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12SMS Pharmaceuticals LtdSMSPHARMA | 48.7/100Mixed-negative evidence100% evidence | TURNING | 19.1/35 Revenue 10.2% · PAT 41.7% · OPM change 0 pp 100% evidence | 11.3/25 ROCE 13.3% · OPM 20% 100% evidence | 10.3/20 P/E 42.4× · PEG 1.53 100% evidence | 8.0/20 RS sector -2.8% · RS bench 32.7% · 1Y 96.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 11.3 + 10.3 + 8 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Morepen Laboratories LtdMOREPENLAB | 48.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 20.3/35 Revenue 9.5% · PAT 51.6% · OPM change 8 pp 100% evidence | 8.5/25 ROCE 8.1% · OPM 14% 100% evidence | 9.7/20 P/E 54× · PEG 1.68 100% evidence | 10.0/20 RS sector -16.2% · RS bench 130.1% · 1Y 134.8%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.3 + 8.5 + 9.7 + 10 = 48.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Blue Jet Healthcare LtdBLUEJET | 46.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 5.8/35 Revenue -27.5% · PAT -34.6% · OPM change -1 pp 100% evidence | 21.0/25 ROCE 26.1% · OPM 33% 100% evidence | 13.8/20 P/E 45.8× · PEG 1.39 100% evidence | 5.9/20 RS sector -39.2% · RS bench 12% · 1Y -23.6%10 of 10 weeks ahead 70% evidence |
| Exact sum: 5.8 + 21 + 13.8 + 5.9 = 46.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 15Supriya Lifescience LtdSUPRIYA | 45.3/100Mixed-negative evidence100% evidence | FADING | 16.1/35 Revenue 28.2% · PAT 11.2% · OPM change -11 pp 100% evidence | 17.1/25 ROCE 25.2% · OPM 25% 100% evidence | 6.9/20 P/E 36.5× · PEG 3.11 100% evidence | 5.2/20 RS sector -11.2% · RS bench 20.4% · 1Y 38.4%8 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 17.1 + 6.9 + 5.2 = 45.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 16Concord Biotech LtdCONCORDBIO | 37.8/100Mixed-negative evidence94% evidence | BREAKING OUT | 9.2/35 Revenue -6.7% · PAT -23.3% · OPM change 2 pp 100% evidence | 14.9/25 ROCE 17.1% · OPM 32% 100% evidence | 6.7/20 P/E 56.7× · PEG 5.67 100% evidence | 7.0/20 RS sector -23.6% · RS bench 16.4% · 1Y -9.2%10 of 10 weeks ahead 70% evidence |
| Exact sum: 9.2 + 14.9 + 6.7 + 7 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Jubilant Pharmova LtdJUBLPHARMA | 37.6/100Mixed-negative evidence93% evidence | TURNING | 11.8/35 Revenue 16.3% · PAT -23% · OPM change -4 pp 100% evidence | 6.8/25 ROCE 9% · OPM 11% 100% evidence | 13.9/20 P/E 42.1× · PEG 1.17 65% evidence | 5.1/20 RS sector -23% · RS bench 5.6% · 1Y -4.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 6.8 + 13.9 + 5.1 = 37.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18Piramal Pharma LtdPPLPHARMA | 35.2/100Mixed-negative evidence71% evidence | LEADER | 13.0/35 Revenue 0.8% · PAT -80% · OPM change 3 pp 74% evidence | 1.4/25 ROCE 2.5% · OPM 9% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.8/20 RS sector -10.9% · RS bench 21.1% · 1Y 5.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 1.4 + 10 + 10.8 = 35.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Solara Active Pharma Sciences LtdSOLARA | 34.7/100Adverse evidence83% evidence | TURNING | 7.9/35 Revenue 15.6% · PAT -80% · OPM change -2 pp 100% evidence | 3.8/25 ROCE 4.9% · OPM 16% 100% evidence | 8.5/20 P/E 843× · PEG — 15% evidence | 14.5/20 RS sector 1.9% · RS bench 38.7% · 1Y 12.7%8 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 3.8 + 8.5 + 14.5 = 34.7 · Decision use: Price leads the evidence: RS versus the benchmark is 38.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Hikal LtdHIKAL | 33.0/100Adverse evidence81% evidence | BREAKING OUT | 11.6/35 Revenue -5.4% · PAT -80% · OPM change 2.6 pp 74% evidence | 4.3/25 ROCE 3.5% · OPM 9.2% 100% evidence | 7.4/20 P/E 65.4× · PEG — 50% evidence | 9.7/20 RS sector -21.7% · RS bench 6.9% · 1Y -14.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 11.6 + 4.3 + 7.4 + 9.7 = 33 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21OneSource Specialty Pharma LtdONESOURCE | 27.5/100Adverse evidence71% evidence | BASING | 11.3/35 Revenue 4.3% · PAT -80% · OPM change 0 pp 74% evidence | 3.3/25 ROCE 0.6% · OPM 27% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.9/20 RS sector -27.3% · RS bench -0.8% · 1Y -15%3 of 12 weeks ahead 100% evidence |
| Exact sum: 11.3 + 3.3 + 10 + 2.9 = 27.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Syngene International LtdSYNGENE | 23.6/100Adverse evidence100% evidence | BASING | 6.7/35 Revenue -3.4% · PAT -56.4% · OPM change -11.3 pp 100% evidence | 8.6/25 ROCE 10% · OPM 12.3% 100% evidence | 8.1/20 P/E 52.2× · PEG 7.87 100% evidence | 0.2/20 RS sector -44.2% · RS bench -22.8% · 1Y -41%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.7 + 8.6 + 8.1 + 0.2 = 23.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Dishman Carbogen Amcis LtdDCAL | 22.1/100Adverse evidence87% evidence | ASLEEP | 7.0/35 Revenue 0.2% · PAT -80% · OPM change -11 pp 100% evidence | 4.8/25 ROCE 3.1% · OPM 9% 100% evidence | 6.4/20 P/E 145× · PEG 2.65 65% evidence | 3.9/20 RS sector -31% · RS bench -18.6% · 1Y -39.5%3 of 10 weeks ahead 70% evidence |
| Exact sum: 7 + 4.8 + 6.4 + 3.9 = 22.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Cohance Lifesciences LtdCOHANCE | 20.6/100Adverse evidence82% evidence | BREAKING OUT | 3.0/35 Revenue -19.8% · PAT -80% · OPM change -19.7 pp 95% evidence | 6.8/25 ROCE 5.8% · OPM 0.3% 76% evidence | 5.5/20 P/E 156× · PEG — 50% evidence | 5.3/20 RS sector -33.4% · RS bench -9.2% · 1Y -52.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 3 + 6.8 + 5.5 + 5.3 = 20.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Acutaas Chemicals Ltd's share price today?
Acutaas Chemicals Ltd trades at ₹3,384, +134.6% over the past year. The company is valued at ₹27,703 Cr. The stock sits at 87% of its 52-week range of ₹1,300–₹3,695, +26.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 124 weeks in. — as of 11 September 2026.
What were Acutaas Chemicals Ltd's latest quarterly results?
Acutaas Chemicals Ltd reported revenue of ₹330 Cr and net profit of ₹75.0 Cr for the Jun 26 quarter. Revenue rose 59.4% and profit rose 70.5% year on year. Earnings per share were ₹9.07. The operating margin was 34.0%, 9.0 pp higher than a year earlier. — as of 11 September 2026.
What is Acutaas Chemicals Ltd's revenue?
Acutaas Chemicals Ltd reported revenue of ₹330 Cr in the Jun 26 quarter, +59.4% year on year. For the full FY26 fiscal year, revenue was ₹1,339 Cr (+33.0%). Over the last 9 years revenue compounded at 26.6% a year. — as of 11 September 2026.
What is Acutaas Chemicals Ltd's profit?
Acutaas Chemicals Ltd earned ₹75.0 Cr of net profit in the Jun 26 quarter, +70.5% year on year — the 7th straight quarter of growth. Full-year FY26 profit was ₹356 Cr. The operating margin ran 34.0% in the latest quarter. — as of 11 September 2026.
What is Acutaas Chemicals Ltd's market cap?
Acutaas Chemicals Ltd's market capitalisation is ₹27,703 Cr at a share price of ₹3,384. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Acutaas Chemicals Ltd's P/E ratio?
Acutaas Chemicals Ltd trades at a P/E of 71.7×, at the 80th percentile of its own 5-year range, against a long-run median of 59.5×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Acutaas Chemicals Ltd pay a dividend?
Yes — Acutaas Chemicals Ltd's dividend payout was 6% of profit in FY26, and it recorded a payout in 5 of its last 10 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Acutaas Chemicals Ltd overvalued?
On its own history, Acutaas Chemicals Ltd looks expensive: its P/E of 71.7× sits at the 80th percentile of its 5-year range (long-run median 59.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 11 September 2026.
Is Acutaas Chemicals Ltd growing?
Yes — Acutaas Chemicals Ltd is growing: latest-quarter revenue +59.4% year on year, profit +70.5%, and the margin +9.0 pp at 34.0%. The 9-year compound rates are 26.6% (revenue) and 45.7% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Acutaas Chemicals Ltd performing?
Acutaas Chemicals Ltd is in a confirmed uptrend, 124 weeks in. Its latest quarter's revenue rose 59.4% and profit rose 70.5% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 55 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Acutaas Chemicals Ltd in?
Mixed — growth is normalizing off a hyper-growth base: profit growth has eased from +228.6% at its peak to +103.7% but is still expanding, ROCE lifting at 32.0%. The read comes from the last 12 quarters of growth (revenue growth +41.0% latest, profit growth +103.7% latest, eps growth +104.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Acutaas Chemicals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 124 of stage 2), trading +26.3% versus its 200-day average and at 87% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Acutaas Chemicals Ltd beating the market?
On recent form, yes — Acutaas Chemicals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 55 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.0 years the stock moved +457% against the NIFTY 500's +53% — ahead of the index over the full window. — as of 11 September 2026.
Will Acutaas Chemicals Ltd's share price go up?
This page publishes no price forecast for Acutaas Chemicals Ltd. What it measures instead: the share price is ₹3,384, the price is in a confirmed uptrend 124 weeks in. Its P/E of 71.7× sits at the 80th percentile of its own 5-year range. — as of 11 September 2026.
Who owns Acutaas Chemicals Ltd?
Promoters hold 32.7% of Acutaas Chemicals Ltd, foreign institutions 21.6%, domestic institutions 19.6% and the public 26.2% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 8.7 points over 8 quarters. — as of 11 September 2026.
Does Acutaas Chemicals Ltd have too much debt?
No — Acutaas Chemicals Ltd's debt-to-equity is 0.02, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹36.0 Cr against equity of ₹1,654 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Acutaas Chemicals Ltd's capex?
Acutaas Chemicals Ltd spent ₹867 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹413 Cr, with ₹332 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Acutaas Chemicals Ltd's cash flow?
Acutaas Chemicals Ltd generated ₹292 Cr of operating cash flow in FY26 and ₹−121 Cr of free cash flow after ₹413 Cr of capital spending. Reported profit that year was ₹356 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Acutaas Chemicals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 95% of Acutaas Chemicals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹292 Cr against reported profit of ₹356 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Acutaas Chemicals Ltd in its business cycle?
Acutaas Chemicals Ltd's FY26 operating margin was 36.0%, against a 10-year band of 14.0%–36.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 34.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Acutaas Chemicals Ltd's price assume?
At its price on 25 August 2026, Acutaas Chemicals Ltd was priced for profit growth of about 30.9% a year. Profit itself has compounded 45.7% a year over the past 9 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Acutaas Chemicals Ltd story?
The sharpest disagreement: the engine is strong, but at the 80th percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Acutaas Chemicals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Acutaas Chemicals Ltd is strength at full price. The numbers are improving — and a P/E at the 80th percentile of its own range says the market knows. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!